OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
General Outlook
In simple terms, OraSure Technologies, Inc. has 73.484 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.411% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.084%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.109%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.107% return, is a testament to OraSure Technologies, Inc.'s adeptness in optimizing resource deployment. OraSure Technologies, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.126%. Furthermore, the proficiency of OraSure Technologies, Inc. in capital utilization is underscored by a remarkable 0.086% return on capital employed.
Stock Prices
OraSure Technologies, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $7.29, while its low point bottomed out at $7.1. This variance in figures offers investors a lucid insight into the roller-coaster ride that is OraSure Technologies, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”